Many eukaryotic and viral mRNAs are modified at their 5' ends by addition of 7-Methylguanosine (N7-methyl guanosine or m7G), known as "Cap". "Capping" of the mRNA structure plays a crucial role in a variety of cellular processes which include translation initiation, splicing, intracellular transport and turnover. Capped mRNAs are generally more efficiently translated in wheat germ and reticulocyte in vitro translation systems, and they are less susceptible to exonuclease degradation during microinjection experiments compared to uncapped mRNAs.
Cap analogs are enzymatically incorporated at the RNA 5'-end by bacteriophage T7 RNA Polymerase-mediated in vitro Transcription.
 Gingras et al. (1999) eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68:913.
 Izaurralde et al. (1994) A nuclear cap binding protein complex involved in pre-mRNA splicing. Cell 78:657.
 Izaurralde et al. (1992) A cap binding protein that may mediate nuclear export of RNA polymerase II-transcribed RNAs. J. Cell Biol. 118:1287.
 Beelman et al. (1998) An essential component of the decapping enzyme required for normal rates of mRNA turnover. Nature 382:642.
 Paterson et al. (1979) Efficient translation of prokaryotic mRNAs in a eukaryotic cell-free system requires addition of a cap structure. Nature 279:692.
 Drummond et al. (1985) The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes. Nucl. Acids Res. 13:375.
 Pasquinelli et al. (1995) Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. RNA 1:957.
 Grudzien et al. (2007) Synthesis of Anti-Reverse Cap Analogs (ARCAs) and their Applications in mRNA Translation and Stability. Methods Enzymol. 431:203.